Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors
MetadataShow full item record
CitationChong, Curtis R., Lori J. Wirth, Mizuki Nishino, Aileen B. Chen, Lynette M. Sholl, Matthew H. Kulke, Ciaran J. McNamee, Pasi A. Jänne, and Bruce E. Johnson. 2014. “Chemotherapy for Locally Advanced and Metastatic Pulmonary Carcinoid Tumors.” Lung Cancer 86 (2) (November): 241–246. doi:10.1016/j.lungcan.2014.08.012.
The optimal management of locally advanced and metastatic pulmonary carcinoid tumors remains to be determined.
Materials and methods
A retrospective review was conducted on patients with typical and atypical pulmonary carcinoid tumors treated at our institutions between 1990 and 2012.
300 patients were identified with pulmonary carcinoid, (80 patients with atypical carcinoid), of whom 29 presented with metastatic disease (16 atypical). Of evaluable patients, 26 (41%) with stages I–III atypical carcinoid tumors recurred at a median time of 3.7 years (range, 0.4–32), compared to 3 (1%) patients with typical carcinoid (range, 8–12.3). 39 patients were treated with chemotherapy, including 30 patients with metastatic disease (27 atypical), and 7 patients were treated with adjuvant platinum–etoposide chemoradiation (6 atypical, 1 typical, 6 stage IIIA, 1 stage IIB). At a median follow-up of 2 years there were 2 recurrences in the 7 patients receiving adjuvant treatment. Median survival after diagnosis of metastatic disease for patients with atypical pulmonary carcinoid was 3.3 years with a 5-year survival of 24%. Treatment regimens showing efficacy in pulmonary carcinoid include 15 patients treated with octreotide-based therapies (10% response rate (RR), 70% disease control rate (DCR), 15 month median progression-free survival (PFS)), 13 patients treated with etoposide + platinum (23% RR, 69% DCR, 7 month median PFS), and 14 patients treated with temozolomide-based therapies (14% RR, 57% DCR, 10 month median PFS). 8 of 10 patients with octreotide-avid disease treated with an octreotide-based regimen experienced disease control (1 partial response, 7 stable disease) for a median of 18 months (range 6–72 months).
These results support our previous finding that a subset of pulmonary carcinoid tumors are responsive to chemotherapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32706203
- HMS Scholarly Articles